 Novo Nordisk AS NYSE: NVO will acquire Prothena Corporation plcs NASDAQ: PRTA and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy designed to deplete the amyloid deposits associated with the disease pathology of ATTR amyloidosis. 